HUTCHMED (China) (HMDCF) Raw Materials (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Raw Materials came in at $25.1 million in Q2 2026, up 2.82% year-over-year from $24.4 million in Q2 2025, and up 11.88% quarter-over-quarter from $22.5 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Raw Materials (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Raw Materials for 12 consecutive years, with $25.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Raw Materials rose 2.82% year-over-year to $25.1 million in Q2 2026; TTM through Jun 2026 was $25.1 million, a 2.82% increase from a year earlier, with the FY2025 full-year figure at $22.5 million, down 7.79% from the prior year.
- Raw Materials was $25.1 million for Q2 2026 at HUTCHMED (China), up from $22.5 million in the prior quarter.
- Over five years, Raw Materials peaked at $27.4 million in Q4 2022 and troughed at $21.6 million in Q2 2022.
- A 5-year average of $24.9 million and a median of $24.8 million in 2024 frame the typical range for Raw Materials.
- Across the five-year window, Raw Materials jumped 163.48% in 2022 and retreated 9.09% in 2024, its largest moves.
- Over 5 years, Raw Materials stood at $27.4 million in 2022, then fell by 2.22% to $26.8 million in 2023, then decreased by 9.09% to $24.3 million in 2024, then declined by 7.79% to $22.5 million in 2025, then advanced by 11.88% to $25.1 million in 2026.
- The last three Raw Materials figures came in at $25.1 million (Q2 2026), $22.5 million (Q4 2025), and $24.4 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 210.98 Bn | 196.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.24 Bn | 178.06 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.38 Bn | 124.53 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.97 Bn | 74.97 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.80 Bn | 49.67 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.09 Bn | 30.78 Bn | 992.69 Mn |
| 8 | Biogen | 31.34 Bn | 30.05 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.12 Mn |
| Dec 31, 2025 | 22.45 Mn |
| Jun 30, 2025 | 24.43 Mn |
| Dec 31, 2024 | 24.35 Mn |
| Jun 30, 2024 | 24.79 Mn |
| Dec 31, 2023 | 26.78 Mn |
| Jun 30, 2023 | 27.23 Mn |
| Dec 31, 2022 | 27.39 Mn |
| Jun 30, 2022 | 21.61 Mn |
| Dec 31, 2021 | 15.84 Mn |
| Jun 30, 2021 | 8.20 Mn |
| Dec 31, 2020 | 4.50 Mn |
| Jun 30, 2020 | 1.37 Mn |
| Dec 31, 2019 | 2.27 Mn |
| Sep 30, 2019 | 1.77 Mn |
| Jun 30, 2019 | 1.87 Mn |
| Mar 31, 2019 | 1.33 Mn |
| Dec 31, 2018 | 652,000.00 |
| Jun 30, 2018 | 639,000.00 |
| Dec 31, 2017 | 314,000.00 |